相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer
Jianghua Wu et al.
MODERN PATHOLOGY (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Artificial intelligence-assisted decision making for prognosis and drug efficacy prediction in lung cancer patients: a narrative review
Jingwei Li et al.
JOURNAL OF THORACIC DISEASE (2021)
CT-Based Hand-crafted Radiomic Signatures Can Predict PD-L1 Expression Levels in Non-small Cell Lung Cancer: a Two-Center Study
Zekun Jiang et al.
JOURNAL OF DIGITAL IMAGING (2021)
Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients
Stefano Bracci et al.
RADIOLOGIA MEDICA (2021)
Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images
Wei Mu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features
Qiang Wen et al.
FRONTIERS IN ONCOLOGY (2021)
Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images
Panwen Tian et al.
THERANOSTICS (2021)
Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result
Mengmeng Jiang et al.
ACADEMIC RADIOLOGY (2020)
Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas
Jiyoung Yoon et al.
THORACIC CANCER (2020)
Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography
Kang Zhang et al.
CELL (2020)
Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy
Wei Chang Colin Tan et al.
CANCER COMMUNICATIONS (2020)
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials
Hossein Borghaei et al.
CANCER (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A CT-derived deep neural network predicts for programmed death ligand-1 expression status in advanced lung adenocarcinomas
Ying Zhu et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
The application of artificial intelligence and radiomics in lung cancer
Yaojie Zhou et al.
PRECISION CLINICAL MEDICINE (2020)
End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography
Diego Ardila et al.
NATURE MEDICINE (2019)
18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer
Mario Jreige et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
J. M. Kim et al.
ANNALS OF ONCOLOGY (2016)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
Joseph McLaughlin et al.
JAMA ONCOLOGY (2016)
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih-Hao Chang et al.
CELL (2015)